CLDN18.2 ADCs "A Real Step Forward" for Stomach Cancer.

Sonesitatug vedotin and arcotatug tavatecan improved overall survival as third- or later-line treatments in CLDN18.2-positive gastric or gastroesophageal carcinomas.

• Why it matters: Patients with CLDN18.2-positive gastric or gastroesophageal carcinomas have very limited treatment options after earlier lines, creating a need for effective later-line therapies.
• What they did: Two phase III trials, CLARITY-Gastric01 and G-HOPE-001, evaluated the CLDN18.2-targeting ADCs sonesitatug vedotin and arcotatug tavatecan in this patient population.
• The result: The ADCs’ overall survival improvements suggest they could be effective third- or later-line treatments for CLDN18.2-positive gastric or gastroesophageal carcinomas.